Displaying 1 - 10 of 12 for Cancer - Lymphoma
  • CARPASCIO Study (H-33133)
    • The purpose of this study is to see whether this therapy might help people with lymphoma or leukemia after a stem cell transplantation from a donor.
  • CHARKALL Study (H-23574)
    • Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL. The lymphoma, MM or CLL has come back or has not gone away after treatment. This is a gene transfer research study using special immune cells.
  • CITADEL Study (H-33900)
    • The purpose of this study is to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma.
  • CIVIC Study (H-39297)
    • The purpose of this study is to investigate the efficacy of autologous Epstein-Barr virus (EBV)-specific T cells for the treatment of EBV positive diffuse large B cell lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease.
  • GRALE Study (H-29617)
    • The purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique.
  • MABEL Study (H-35253)
    • In this study, we want to find out if we can use banked MABEL CTLs to treat HD or NHL, T/NK-lymphoproliferative disease and severe chronic active Epstein Barr Virus (CAEBV).
  • MOHEL Study (H-8701)
    • Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
  • Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (H-38468)
    • The purpose of this study is to determine the safety and efficacy of KTE-C19 in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.
  • SAGAN Study (H-31970)
    • The purpose of this study is to find the biggest dose of chimeric T cells that is safe, see how long the T cell with each sort of chimeric receptor lasts, learn what the side effects are.
  • TACTAL Study (H-27471)
    • This a research study using special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.